Skip to main content
On Our Radar

Phase 1b Results Reported for Potentially First-in-Class Parkinson’s Treatment

By November 22, 2021May 26th, 2022No Comments

Phase 1b Results Reported for Potentially First-in-Class Parkinson’s Treatment

Boston-based biopharma company Yumanity Therapeutics announced last week that its drug candidate, YTX-7739, met its primary end points in a Phase 1b trial in patients with mild to moderate Parkinson’s disease.

Recent discoveries about the role of lipids in the activity of alpha-synuclein have led to the development of a lipidopathy hypothesis and opened up a new avenue of research; targeting lipids represents a first-in-class mechanism of action in the treatment of Parkinson’s. YTX-7739 inhibits stearoyl-CoA desaturase (SCD), an enzyme involved in the production of fatty acids involved in various cellular processes. Inhibiting SCD appears to normalize the way alpha-synuclein interacts with cell membranes and prevent its accumulation.

In the Phase 1b trial, 20 adults with Parkinson’s were randomized to receive placebo or YTZ-7739 once daily for 28 days. YTX-7739 demonstrated a 20%-40% reduction in SCD activity, a level expected to be clinically relevant. Results from electroencephalograms suggest improved brain function in patients treated with YTX-7739, but there were no significant differences in clinical measures of Parkinson’s, a result Yumanity says is not surprising given the short trial duration.

Based on these positive results, Yumanity plans to advance YTX-7739 to Phase 2 testing in 2022.

Read about the study
CND Life Sciences

CND Life Sciences is the creator of the Syn-One Test™, the world’s first commercially available test to visualize abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test is an objective, evidence-based diagnostic tool to aid in the diagnosis of Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, or REM sleep behavior disorder.